Octreotide Scan

Home Services Nuclear Medicine Octreotide Scan
Also known as Somatostatin Receptor Scintigraphy, which is a test intended to investigate the presence of neuroendocrine tumors based on tumor cells’ receptor density, in addition to a full body survey if the tumor has metastasized.

Fasting: Is not preferred as you will be requested to considerably increase fluid intake, consequently increasing urination frequency, as you will be requested to empty your bladder immediately prior to the procedure.

Medication contradiction: All medications can be resumed. However, the following medications should be stopped as follows:
  1. Long acting somatostatin inhibitors should be stopped for 4 weeks
  2. Short acting somatostatin inhibitors should be stopped for 1 day
Tracer administration: The radiopharmaceutical tracer will be injected intravenously.

Examination Duration: The imaging process will take up 30 minutes for the first session and up to 2 hours for the second. Imaging will be conducted 4 hours after the injection and again 24 hours later.